Literature DB >> 23459463

Early postprandial glucagon surge affects postprandial glucose levels in obese and non-obese patients with type 2 diabetes.

Junji Kozawa1, Kohei Okita, Hiromi Iwahashi, Kazuya Yamagata, Akihisa Imagawa, Iichiro Shimomura.   

Abstract

Postprandial glucagon secretion was shown to be dysregulated in patients with type 2 diabetes. However, the differences in secretory patterns between obese and non-obese patients and their physiological effects on plasma glucose levels are not fully understood. This study population consisted of 21 (10 obese and 11 non-obese) consecutive patients with type 2 diabetes admitted for glycemic control. A 3-hour mixed-meal tolerance test was performed after glycemic control improved. Six non-diabetic subjects were also enrolled in the test. Postprandial glucagon levels increased after 30 min in diabetic patients but not in non-diabetic subjects. The glucagon levels in obese diabetic patients were significantly higher than those in non-obese diabetic patients, while the percent values of postprandial glucagon levels were not different between these groups. In diabetic patients, there were significant positive correlations between the percent value at 30 min and the early postprandial glucose levels at 0, 15 and 30 min and the areas under the curve (AUC0-30 and AUC30-90). Interestingly, the ratio of this percent glucagon value to the C-peptide level at 30 min was significantly associated with the late half of the postprandial glucose levels at 90, 120, 150 and 180 min and the AUC90-180. This is the first report that demonstrates the glucagon secretory patterns and the close correlations in detailed time course between the early postprandial glucagon response and the early and the late half of the postprandial glucose levels in obese and non-obese patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23459463     DOI: 10.1507/endocrj.ej13-0018

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway.

Authors:  May-Yun Wang; Hai Yan; Zhiqing Shi; Matthew R Evans; Xinxin Yu; Young Lee; Shiuhwei Chen; Annie Williams; Jacques Philippe; Michael G Roth; Roger H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-09       Impact factor: 11.205

2.  An AlphaScreen Assay for the Discovery of Synthetic Chemical Inhibitors of Glucagon Production.

Authors:  Matthew R Evans; Shuguang Wei; Bruce A Posner; Roger H Unger; Michael G Roth
Journal:  J Biomol Screen       Date:  2015-12-16

3.  Basal hypersecretion of glucagon and insulin from palmitate-exposed human islets depends on FFAR1 but not decreased somatostatin secretion.

Authors:  H Kristinsson; E Sargsyan; H Manell; D M Smith; S O Göpel; P Bergsten
Journal:  Sci Rep       Date:  2017-07-05       Impact factor: 4.379

4.  Positive correlation between fasting plasma glucagon and serum C-peptide in Japanese patients with diabetes.

Authors:  Yoshiya Hosokawa; Junji Kozawa; Hitoshi Nishizawa; Dan Kawamori; Norikazu Maeda; Michio Otsuki; Taka-Aki Matsuoka; Hiromi Iwahashi; Iichiro Shimomura
Journal:  Heliyon       Date:  2019-05-13

Review 5.  Islet Function in the Pathogenesis of Cystic Fibrosis-Related Diabetes Mellitus.

Authors:  Efraim Westholm; Anna Wendt; Lena Eliasson
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2021-07-13

6.  Postabsorptive hyperglucagonemia in patients with type 2 diabetes mellitus analyzed with a novel enzyme-linked immunosorbent assay.

Authors:  Toshihiro Matsuo; Jun-Ichiro Miyagawa; Yoshiki Kusunoki; Masayuki Miuchi; Takashi Ikawa; Takafumi Akagami; Masaru Tokuda; Tomoyuki Katsuno; Akira Kushida; Takashi Inagaki; Mitsuyoshi Namba
Journal:  J Diabetes Investig       Date:  2015-08-24       Impact factor: 4.232

7.  Effect of Dietary Macronutrients on Postprandial Glucagon and Insulin Release in Obese and Normal-Weight Women.

Authors:  Tomasz Wikarek; Piotr Kocełak; Aleksander J Owczarek; Jerzy Chudek; Magdalena Olszanecka-Glinianowicz
Journal:  Int J Endocrinol       Date:  2020-04-30       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.